An interventional study of albendazole and dexamethasone in Epilepsy and Cysticercosis, sponsored by Johns Hopkins University. Completed. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-25.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment
Among 16 studies in Epilepsy by Johns Hopkins University — 2 open to participants now, 3 under way, none of them phase 3. Epilepsy · Johns Hopkins University.
Among the 16 studies in Epilepsy by Johns Hopkins University, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2000, is one of 6 with no phase, and was the 1st registered.
1,848 studies on the registry are indexed under Epilepsy; 422 are open to participants now.
This study's enrollment of 120 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →2 of the 16 studies in Epilepsy by Johns Hopkins University are open now, in 1 country. Each count lists the studies.
Of the 285 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 149 (52%) stop at 75 or younger; 139 take children under 18; 56 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 2 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2000.
Median enrollment 26 across the 12 interventional studies, 71 across the 4 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
Johns Hopkins University is the lead sponsor of 1,815 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
2 of the studies in Epilepsy by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
| NCT05289934Johns Hopkins UniversityEffects of Recorded Music on Clinical and EEG Seizure Activity | 2027-03-01 |
Among the 16 studies in Epilepsy by Johns Hopkins University, from their registry updates:
OBJECTIVES: I. Determine the effect of antiparasitic treatment with albendazole on the severity and duration of epilepsy due to neurocysticercosis.
II. Determine the effect of a short course of albendazole on Taenia solium cysts present in the brain.
III. Determine the natural regression of cerebral T. solium cysts in patients given placebo and their response to treatment at the end of the study.
PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are randomized to receive either albendazole and dexamethasone or placebo.
Patients receive phenytoin daily starting on day 1 and continuing until seizure free for 1 year. Albendazole and dexamethasone or placebo only is administered orally once daily on days 5-15.
Patients are asked to maintain a diary. Patients are followed on day 15 and 30, then every 3 months for 3 years.
Completion date provided represents the completion date of the grant per OOPD records
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
No study locations are listed for this record.
The record gives a start of May 2000 and a completion of Mar 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2001. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albendazole